JP2005515236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005515236A5 JP2005515236A5 JP2003561501A JP2003561501A JP2005515236A5 JP 2005515236 A5 JP2005515236 A5 JP 2005515236A5 JP 2003561501 A JP2003561501 A JP 2003561501A JP 2003561501 A JP2003561501 A JP 2003561501A JP 2005515236 A5 JP2005515236 A5 JP 2005515236A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- west nile
- vaccine
- virus
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims 16
- 241000710886 West Nile virus Species 0.000 claims 11
- 239000002671 adjuvant Substances 0.000 claims 9
- 241000283073 Equus caballus Species 0.000 claims 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 239000002270 dispersing agent Substances 0.000 claims 4
- 239000000080 wetting agent Substances 0.000 claims 4
- 229920001400 block copolymer Polymers 0.000 claims 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims 3
- -1 polyoxyethylene Polymers 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 229940032094 squalane Drugs 0.000 claims 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002736 nonionic surfactant Substances 0.000 claims 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 2
- 238000009736 wetting Methods 0.000 claims 2
- 241000271566 Aves Species 0.000 claims 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 claims 1
- 241000701081 Equid alphaherpesvirus 1 Species 0.000 claims 1
- 241000701089 Equid alphaherpesvirus 4 Species 0.000 claims 1
- 241000230501 Equine herpesvirus sp. Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 229920001214 Polysorbate 60 Polymers 0.000 claims 1
- 241000711798 Rabies lyssavirus Species 0.000 claims 1
- 241000194048 Streptococcus equi Species 0.000 claims 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 201000006449 West Nile encephalitis Diseases 0.000 claims 1
- 241000710951 Western equine encephalitis virus Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30833401P | 2001-07-27 | 2001-07-27 | |
| US60/308,334 | 2001-07-27 | ||
| PCT/US2002/023447 WO2003061555A2 (en) | 2001-07-27 | 2002-07-23 | West nile vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010255105A Division JP2011057692A (ja) | 2001-07-27 | 2010-11-15 | ウエストナイルワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005515236A JP2005515236A (ja) | 2005-05-26 |
| JP2005515236A5 true JP2005515236A5 (OSRAM) | 2009-04-09 |
| JP4718778B2 JP4718778B2 (ja) | 2011-07-06 |
Family
ID=27613166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003561501A Expired - Lifetime JP4718778B2 (ja) | 2001-07-27 | 2002-07-23 | ウエストナイルワクチン |
| JP2010255105A Pending JP2011057692A (ja) | 2001-07-27 | 2010-11-15 | ウエストナイルワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010255105A Pending JP2011057692A (ja) | 2001-07-27 | 2010-11-15 | ウエストナイルワクチン |
Country Status (24)
| Country | Link |
|---|---|
| US (8) | US7153513B2 (OSRAM) |
| EP (3) | EP2281572A1 (OSRAM) |
| JP (2) | JP4718778B2 (OSRAM) |
| KR (2) | KR20040028952A (OSRAM) |
| CN (2) | CN1935258B (OSRAM) |
| AU (1) | AU2002365244B2 (OSRAM) |
| BE (1) | BE2014C006I2 (OSRAM) |
| BR (1) | BRPI0211492B1 (OSRAM) |
| CA (1) | CA2452545C (OSRAM) |
| CY (1) | CY2014010I2 (OSRAM) |
| DK (1) | DK1427444T3 (OSRAM) |
| ES (1) | ES2435095T3 (OSRAM) |
| FR (1) | FR14C0016I2 (OSRAM) |
| HR (1) | HRP20040195B1 (OSRAM) |
| HU (2) | HU228690B1 (OSRAM) |
| LU (1) | LU92348I2 (OSRAM) |
| ME (1) | ME00491B (OSRAM) |
| MX (1) | MXPA04000680A (OSRAM) |
| NZ (3) | NZ531265A (OSRAM) |
| PL (2) | PL220846B1 (OSRAM) |
| PT (1) | PT1427444E (OSRAM) |
| RS (1) | RS53184B (OSRAM) |
| WO (1) | WO2003061555A2 (OSRAM) |
| ZA (1) | ZA200401596B (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7425437B2 (en) * | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
| BRPI0211492B1 (pt) * | 2001-07-27 | 2016-06-21 | Pah W Llc | "composição de vacina para uso na prevenção ou melhora de encefalite de west nile em equídeos, e uso de um componente imunogenicamente ativo na preparação da mesma |
| US7585621B2 (en) * | 2003-09-09 | 2009-09-08 | Idexx Laboratories, Inc. | Detection of West Nile virus infection and vaccination |
| US7074555B2 (en) * | 2004-04-28 | 2006-07-11 | Idexx Laboratories, Inc. | Detection of West Nile Virus |
| FR2870126B1 (fr) | 2004-05-17 | 2009-07-17 | Pasteur Institut | Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin |
| CA2582534A1 (en) | 2004-09-09 | 2006-03-16 | Research Development Foundation | Flavivirus variants having phenotypic variation and immunogenic compositions thereof |
| WO2006107655A2 (en) * | 2005-04-01 | 2006-10-12 | Wyeth | Use of wnv dna vaccine in combination with a conventional vaccine to overcome immunogen interference |
| US7959929B2 (en) | 2005-04-21 | 2011-06-14 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
| AU2006245734C1 (en) | 2005-05-12 | 2012-05-24 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| EP1724338A1 (en) * | 2005-05-19 | 2006-11-22 | Crucell Holland B.V. | Methods for the production of a whole-inactivated West Nile Virus vaccine |
| WO2006122964A1 (en) * | 2005-05-19 | 2006-11-23 | Crucell Holland B.V. | Methods for the production of a whole-inactivated west nile virus vaccine |
| BRPI0611581B1 (pt) | 2005-06-24 | 2021-08-03 | Intervet International B.V. | Flavivírus quimérico inativado, composição imunogênica, e, vacina |
| KR101597534B1 (ko) * | 2005-10-19 | 2016-02-26 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 개과 동물의 호흡기 질병 조절을 위한 물질들 및 방법들 |
| WO2007047728A2 (en) * | 2005-10-20 | 2007-04-26 | Wyeth | Compositions and methods for the treatment of canine influenza virus disease |
| AU2006338210A1 (en) * | 2005-12-14 | 2007-08-23 | The Board Of Regents Of The University Of Oklahoma | RNA virus vaccines and methods |
| EA031202B1 (ru) | 2006-06-06 | 2018-11-30 | Янссен Вэксинс Энд Превеншн Б.В. | Антитело человека, обладающее фагоцитарной активностью против стафилококков, и его применение |
| AU2008324780A1 (en) * | 2007-11-06 | 2009-05-14 | Pah W Llc | Mycoplasma hyopneumoniae avirulent -adjuvanted live vaccine |
| CA2725329C (en) | 2008-05-23 | 2013-10-01 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| AU2009277107B2 (en) * | 2008-07-30 | 2014-02-27 | University Of Kentucky Research Foundation | Equine disease model for herpesvirus neurologic disease and uses thereof |
| US8821889B2 (en) * | 2008-08-29 | 2014-09-02 | Boehringer Ingelheim Vetmedica, Inc. | West Nile Virus vaccine |
| AU2010303741A1 (en) * | 2009-10-07 | 2012-04-19 | Zoetis W Llc | Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof |
| MX350718B (es) | 2011-03-14 | 2017-09-14 | Boehringer Ingelheim Vetmedica Inc | Vacuna de rinitis equina. |
| CN103045544B (zh) * | 2011-10-17 | 2015-01-14 | 华中农业大学 | 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用 |
| MX367268B (es) * | 2013-05-14 | 2019-08-12 | Zoetis Services Llc | Nuevas composiciones de vacuna que comprenden oligonucleotidos inmunoestimulantes. |
| HK1224177A1 (zh) * | 2013-09-05 | 2017-08-18 | 硕腾服务有限责任公司 | Hendra和nipah病毒g糖蛋白免疫原性組合物 |
| US11033615B2 (en) | 2016-05-31 | 2021-06-15 | The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland | Zika virus vaccine and methods of production |
| PL70842Y1 (pl) * | 2017-08-25 | 2019-06-28 | Gondek Lukasz Kuznia Mocy | Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych |
| CN113905759A (zh) | 2019-02-27 | 2022-01-07 | 罗切斯特大学 | 用于预防和控制马的马流感病毒(eiv)的多价减毒活流感疫苗 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US308334A (en) | 1884-11-18 | Ladder | ||
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US5741696A (en) * | 1992-08-07 | 1998-04-21 | Syntro Corporation | Recombinant equine herpesviruses |
| FR2702373B1 (fr) * | 1993-03-08 | 1996-06-07 | Rhone Merieux | Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable. |
| CN1268393C (zh) * | 1994-05-10 | 2006-08-09 | 惠氏公司 | 经改良修饰的brsv或疫苗 |
| US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| BR9910830A (pt) | 1998-06-04 | 2001-02-13 | Us Gov Health & Human Serv | Vacinas de ácido nucléico para prevenção de infecção flavivìrus |
| WO2002028165A2 (en) * | 2000-10-04 | 2002-04-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| WO2002068637A2 (en) | 2000-10-20 | 2002-09-06 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-based treatment of diseases or conditions related to west nile virus infection |
| WO2002083903A2 (en) | 2001-02-28 | 2002-10-24 | Brown University Research Foundation | West nile virus epitopes and uses thereof |
| EP1372711A4 (en) * | 2001-03-12 | 2005-06-01 | Univ Yale | COMPOSITIONS AND METHODS OF WEST NIL VIRUS POLYPEPTIDES |
| US20030104008A1 (en) * | 2001-04-06 | 2003-06-05 | Loosmore Sheena May | Recombinant vaccine against west nile virus |
| FR2823222B1 (fr) * | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
| BRPI0211492B1 (pt) * | 2001-07-27 | 2016-06-21 | Pah W Llc | "composição de vacina para uso na prevenção ou melhora de encefalite de west nile em equídeos, e uso de um componente imunogenicamente ativo na preparação da mesma |
| US7785799B2 (en) | 2002-08-16 | 2010-08-31 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain III antigens |
-
2002
- 2002-07-23 BR BRPI0211492A patent/BRPI0211492B1/pt active IP Right Grant
- 2002-07-23 RS YU8004A patent/RS53184B/sr unknown
- 2002-07-23 MX MXPA04000680A patent/MXPA04000680A/es active IP Right Grant
- 2002-07-23 NZ NZ531265A patent/NZ531265A/en not_active IP Right Cessation
- 2002-07-23 ME MEP-2008-784A patent/ME00491B/me unknown
- 2002-07-23 NZ NZ570270A patent/NZ570270A/en not_active Application Discontinuation
- 2002-07-23 HU HU0401606A patent/HU228690B1/hu active Protection Beyond IP Right Term
- 2002-07-23 CN CN2006101058113A patent/CN1935258B/zh not_active Expired - Lifetime
- 2002-07-23 CA CA2452545A patent/CA2452545C/en not_active Expired - Lifetime
- 2002-07-23 WO PCT/US2002/023447 patent/WO2003061555A2/en not_active Ceased
- 2002-07-23 PL PL398575A patent/PL220846B1/pl unknown
- 2002-07-23 EP EP10183615A patent/EP2281572A1/en not_active Withdrawn
- 2002-07-23 DK DK02806585.2T patent/DK1427444T3/da active
- 2002-07-23 PT PT2806585T patent/PT1427444E/pt unknown
- 2002-07-23 JP JP2003561501A patent/JP4718778B2/ja not_active Expired - Lifetime
- 2002-07-23 PL PL368535A patent/PL212212B1/pl unknown
- 2002-07-23 EP EP02806585.2A patent/EP1427444B1/en not_active Expired - Lifetime
- 2002-07-23 ES ES02806585T patent/ES2435095T3/es not_active Expired - Lifetime
- 2002-07-23 KR KR10-2004-7001202A patent/KR20040028952A/ko not_active Ceased
- 2002-07-23 EP EP10183676A patent/EP2283858A3/en not_active Ceased
- 2002-07-23 KR KR1020097010065A patent/KR20090053967A/ko not_active Ceased
- 2002-07-23 AU AU2002365244A patent/AU2002365244B2/en not_active Expired
- 2002-07-23 CN CNB028146646A patent/CN1273189C/zh not_active Expired - Lifetime
- 2002-07-23 HR HRP20040195AA patent/HRP20040195B1/hr not_active IP Right Cessation
- 2002-07-25 US US10/202,716 patent/US7153513B2/en not_active Expired - Lifetime
-
2004
- 2004-02-26 ZA ZA2004/01596A patent/ZA200401596B/en unknown
-
2006
- 2006-10-30 US US11/589,527 patent/US7445787B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,595 patent/US20070231350A1/en not_active Abandoned
- 2006-10-30 US US11/589,515 patent/US20070166324A1/en not_active Abandoned
- 2006-10-30 US US11/589,528 patent/US7648706B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,516 patent/US20070166325A1/en not_active Abandoned
- 2006-10-30 US US11/589,507 patent/US7648705B2/en not_active Expired - Lifetime
- 2006-10-30 US US11/589,523 patent/US20070166326A1/en not_active Abandoned
-
2007
- 2007-02-13 NZ NZ553165A patent/NZ553165A/en not_active IP Right Cessation
-
2010
- 2010-11-15 JP JP2010255105A patent/JP2011057692A/ja active Pending
-
2013
- 2013-10-04 HU HUS1300055C patent/HUS1300055I1/hu unknown
-
2014
- 2014-01-06 LU LU92348C patent/LU92348I2/xx unknown
- 2014-01-31 BE BE2014C006C patent/BE2014C006I2/fr unknown
- 2014-02-20 CY CY2014010C patent/CY2014010I2/el unknown
- 2014-02-21 FR FR14C0016C patent/FR14C0016I2/fr active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005515236A5 (OSRAM) | ||
| Sjölander et al. | Immune responses to ISCOM® formulations in animal and primate models | |
| Nunberg et al. | Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. | |
| Dhakal et al. | Nanoparticle-based vaccine development and evaluation against viral infections in pigs | |
| Maynard | Hepatitis B: global importance and need for control | |
| Gallichan et al. | Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract | |
| Bielinska et al. | Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge | |
| Klinman et al. | CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases | |
| JP4718778B2 (ja) | ウエストナイルワクチン | |
| CA2189979A1 (en) | Improved modified live brsv vaccine | |
| Podda et al. | MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile | |
| Gasparini et al. | Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects | |
| AU766635B2 (en) | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant | |
| CA2383105A1 (en) | Intranasal influenza virus vaccine | |
| Strube et al. | A gE deleted infectious bovine rhinotracheitis marker vaccine for use in improved bovine herpesvirus 1 control programs | |
| EP1265633B1 (de) | Adjuvans für vakzinen | |
| Goldwater | Randomized, comparative trial of 20 μg vs 40 μg Engerix B vaccine in hepatitis B vaccine non-responders | |
| US20030129161A1 (en) | Interleukin-12 as a veterinary vaccine adjuvant | |
| EP1154792B1 (en) | Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant | |
| Simms et al. | Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs | |
| EP0604727A1 (en) | Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen | |
| WO2005016246A3 (en) | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases | |
| EP1987840B1 (en) | Prime-boost vaccine for the protection of equines against viral infection | |
| CN101466370A (zh) | 纳米乳剂疫苗 | |
| World Health Organization | Interim recommendations for use of the Valneva VLA2001 vaccine against COVID 19: interim guidance, first issued 18 August 2022 |